AI assistant
Fulcrum Therapeutics, Inc. — Director's Dealing 2020
Feb 5, 2020
32881_dirs_2020-02-05_0b805a2f-30ad-4ef7-8f3d-9789da69e1f5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Fulcrum Therapeutics, Inc. (FULC)
CIK: 0001680581
Period of Report: 2020-02-03
Reporting Person: Cadavid Diego (SVP Clinical Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-03 | Common Stock | S | 2143 | $17.3317 | Disposed | 68928 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.06 to $17.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.